

INTRABIOTICS PHARMACEUTICALS INC /DE

Form 8-K

October 08, 2004

Table of Contents

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **October 6, 2004**

IntraBiotics Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware	0-29993	94-3200380
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

**2483 East Bayshore Road, Suite 100
Palo Alto, California 94303**

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(650) 526-6800**

Not Applicable

(Former name or former address, if changed since last report.)

TABLE OF CONTENTS

Item 8.01 Other Events.

Item 9.01 Financial Statements and Exhibits.

SIGNATURE

EXHIBIT INDEX

EXHIBIT 99.1

Table of Contents

Item 8.01 Other Events.

On October 6, 2004, IntraBiotics Pharmaceuticals, Inc. (the *Company*) issued a press release announcing that it had retained Lazard to advise the Company in evaluating strategic options.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits.

99.1 Press release dated October 6, 2004.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

INTRABIOTICS PHARMACEUTICALS, INC.

Date: October 7, 2004

/s/ David Tucker

David Tucker
Principal Financial Officer

Table of Contents

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press release dated October 6, 2004.